Scarica l'app Stockscreener
391.02
0.26%
-1.03
Dopo l'orario di chiusura:
392.01
0.99
+0.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$392.05
Aprire:
$392.13
Volume 24 ore:
1.31M
Relative Volume:
0.81
Capitalizzazione di mercato:
$100.25B
Reddito:
$11.39B
Utile/perdita netta:
$3.64B
Rapporto P/E:
27.95
EPS:
13.99
Flusso di cassa netto:
$3.50B
1 W Prestazione:
-1.04%
1M Prestazione:
-16.52%
6M Prestazione:
-17.59%
1 anno Prestazione:
-20.74%
Intervallo 1D:
$389.38
$394.53
Intervallo di 1 settimana:
$383.64
$396.13
Portata 52W:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Confronta VRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Will Vertex Pharmaceuticals Incorporated outperform the marketWeekly Trend Recap & Real-Time Buy Signal Alerts - Newser
Using Bollinger Bands to evaluate Vertex Pharmaceuticals IncorporatedJuly 2025 Market Mood & Daily Oversold Stock Bounce Ideas - Newser
What does recent volatility data suggest for Vertex Pharmaceuticals IncorporatedVolume Spike & Fast Moving Stock Watchlists - Newser
What high frequency data says about Vertex Pharmaceuticals IncorporatedJuly 2025 Highlights & Weekly Breakout Opportunity Watchlist - Newser
Should you wait for a breakout in Vertex Pharmaceuticals IncorporatedJuly 2025 Intraday Action & Community Consensus Stock Picks - Newser
When is the best time to exit Vertex Pharmaceuticals IncorporatedJuly 2025 Pullbacks & High Yield Stock Recommendations - Newser
Signal strength of Vertex Pharmaceuticals Incorporated stock in tech scannersInflation Watch & Real-Time Price Movement Reports - Newser
DBS Bank Adjusts Price Target on Vertex Pharmaceuticals to $480 From $600, Maintains Buy Rating - MarketScreener
Can Vertex Pharmaceuticals Incorporated recover in the next quarter2025 Fundamental Recap & Weekly Momentum Stock Picks - Newser
Will earnings trigger a reversal in Vertex Pharmaceuticals IncorporatedJuly 2025 Technicals & Fast Exit Strategy with Risk Control - Newser
Risk adjusted return profile for Vertex Pharmaceuticals Incorporated analyzed2025 Trading Volume Trends & Daily Growth Stock Tips - Newser
Stock Analysis | Vertex Pharmaceuticals OutlookMixed Signals Amid Strong Fundamentals - AInvest
Volatility clustering patterns for Vertex Pharmaceuticals IncorporatedJuly 2025 Setups & Safe Swing Trade Setup Alerts - Newser
How high can Vertex Pharmaceuticals Incorporated stock goEarnings Miss & Community Supported Trade Ideas - Newser
Is Vertex Pharmaceuticals Incorporated stock reversal real or fakeWeekly Trade Analysis & Fast Exit and Entry Strategy Plans - Newser
How to build a custom watchlist for Vertex Pharmaceuticals Incorporated2025 Pullback Review & Verified Momentum Watchlists - Newser
Visualizing Vertex Pharmaceuticals Incorporated stock with heatmapsJuly 2025 Analyst Calls & Precise Buy Zone Tips - Newser
Maze Therapeutics referred to federal marketing regulators over challenge brought by Vertex - Fierce Pharma
Vertex Pharmaceuticals Incorporated stock trendline breakdownWeekly Gains Report & Real-Time Volume Analysis - Newser
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - sharewise.com
Order flow analysis tools used on Vertex Pharmaceuticals Incorporated2025 Major Catalysts & Real-Time Volume Spike Alerts - Newser
Institutional scanner results for Vertex Pharmaceuticals IncorporatedPortfolio Value Report & Safe Entry Momentum Tips - Newser
National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry - GlobeNewswire
How to monitor Vertex Pharmaceuticals Incorporated with trend dashboardsGDP Growth & Stock Portfolio Risk Control - Newser
Top chart patterns to watch in Vertex Pharmaceuticals IncorporatedEarnings Risk Summary & Free Weekly Watchlist of Top Performers - Newser
Vertex Pharmaceuticals Incorporated stock retracement – recovery analysisMarket Volume Summary & Fast Moving Trade Plans - Newser
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.19%
1.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):